


Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50928X1D1C2	PREDECESSOR SERIAL NO. 10/325,521
 <p><b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i></p>		APPLICANT Dubois, <i>et al.</i>	
		FILING DATE Herewith	GROUP 1614

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**


Document Number	Date	Country	Class	Subclass	Translation Yes   No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Andriole, V.T., The Future of the Quinolones, Drugs, Vol 58, Suppl 2, 1-5 (1999)
	Biedenbach, D.J., et al., Antimicrobial Activity of LB20304 Against Legionella species and Anaerobic Bacteria Using Reference Agar Dilution Methods, Abstract F-170, 37th ICAAC, 9/28-10/1-1997
	Bryskier, A., Update, Anti-infectives, Novelties in the field of fluoroquinolones, Exp. Opin. Invest. Drugs (1997) 6(9):1227-1245
	Chen, D.K., et al., Decreased Susceptibility of Streptococcus Pneumoniae to Fluoroquinolones in Canada, New England Jnl of Medicine, Vol 341, No. 4, 233-239 (July 22, 1999)
	Chu, D.T.W., The Future Role of Quinolones, Exp. Opin. Ther. Patents (1996) 6(8) 711-737
	Discotto, L.F., et al., 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 24-27, 1998, San Diego, CA, USA, Exp. Opin. Invest. Drugs (1998) 7(12) 2061-2977
	Drugline, Molecule of the Month, Drug News Perspect 11(8), October 1998, 505
	Eliopoulos, G.M., Activity of Newer Fluoroquinolones In Vitro Against Gram-Positive Bacteria, Drugs 1999, 58 Suppl 2, 23-28
	Garau, J., The Role of Quinolones in the Treatment of Community-Acquired Pneumonia, Medicina Clinica, Vol 110, Suppl 1, 31-35 (Feb 1998)
	Goldstein, E.J.C., et al., In Vitro Activity of Gemifloxacin (SB 265805) against Anaerobes, Antimicrob. Agents Chemother., Vol 43, No. 9, 2231-2235, Sept. 1999
	Goldstein, E.J.C., Clinical Anaerobic Infections, Anaerobe (1999) 5, 347-350
	Graul, A., et al., SB-265805/LB-20304a Naphthyridine Antibacterial, Drugs Future, Vol 23(11) 1199-1204 (1998)
	Gwaltney, J.M., Sinusitis, Mandell et al., Editors, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 4th Ed., pp. 585-589 (1995)
	Hammerschlag, M.R., Activity of Quinolones Against Chlamydia pneumoniae, Drugs 1999, 58 Suppl 2, 78-81
	Johnson, D.M., et al., Anti-Streptococcal Activity of SB-265805 (LB20304), a Novel Fluoronaphthyridone, Compared With Five Other Compounds, Including Quality Control Guidelines, Diagn Microbiol Infect Dis 1999; 33:87-91
	Ridgway, G.L., Quinolones in Sexually Transmitted Diseases, Drugs 1999, 58 Suppl 2, 92-95

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50928X1D1C2	PREDECESSOR SERIAL NO. 10/325,521
 <p><b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>Use several sheets if necessary</i></p>		APPLICANT Dubois, <i>et al.</i>	
		FILING DATE Herewith	GROUP 1614

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Subclass	Translation Yes   No

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Erwin, M.E., et al., Studies to Establish Quality Control Ranges for SB-265805 (LB20304) When Using National Committee for Clinical Laboratory Standards Antimicrobial Susceptibility Test Methods, Journal of Clinical Microbiology, Jan. 1999, 279-280
	Kim et al., "Safety Evaluation of LB20304, a New Quinolone Antibiotic", Journal of Applied Pharmacology, Vol. 3, pp. 322-326 (1995)
	Kononenko, O., et al., Comparative Antimicrobial Effects of Ciprofloxacin (CI), SB 265805 (SB), and Trovafloxacin (TR) on Staphylococcus aureus in an In Vitro Dynamic Model, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 290, Abstract P766, and poster P766 (ECCMID March 1999, Germany)
	Naber, K.G. et al., In Vitro Activity of SB-265805 versus Gatifloxacin, Moxifloxacin, Trovafloxacin, Ciprofloxacin and Ofloxacin against Uropathogens, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 144, Abstract P222, and poster P222 (ECCMID March 1999, Germany)
	Reinert, R.R., et al., In Vitro Activity of SB-265805 Against Streptococcus pneumoniae in Germany, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 143, Abstract P219, and poster P219 (ECCMID March 1999, Germany)
	Smirnov, A. et al., Gemifloxacin is Effective in Experimental Pneumococcal Meningitis, Clin. Microbiol. and Infection, 1999, Vol. 5, Suppl. 3, 144, Abstract P223, and poster P223 (ECCMID March 1999, Germany)
	Journal of Antimicrobial Chemotherapy, 21st International Congress of Chemotherapy, Birmingham UK, July 4-7, 1999, Suppl. A to Vol. 44 July 1999, pp. 125-127, 130-132, 135-136, 139-142, 144-148; 21st ICC poster nos. P 385, 386, 391, 406, 408, 413, 429, 434, 449, 452, 454, 460-462, 474, 477, 482, 484, 486-488, 491, 492
	Ruf, B.R., et al., Infektiologie, Internist 1999 40:369-380, and English language abstract
	SB-265805, A Potent New Quinolone, 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, San Diego Convention Centre, 105-F Poster Session, New Fluoroquinolones II, September 26th 1998: cover page, contents page and Abstract Nos. F-087 through F-106

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P50928X1D1C2	PREDECESSOR SERIAL NO. 10/325,521
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT Dubois, et al.	
		FILING DATE Herewith	GROUP

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,633,262	5/27/97	Hong et al.			
	AB	5,776,944	7/7/98	Hong et al.			
	AC	5,869,670	2/9/99	Hong et al.			
	AD	5,962,468	10/5/99	Hong et al.			
	AE	4,931,446	06/05/90	Berger-Neel et al.			
	AF	5,756,506	05/26/98	Copeland et al.			
	AG	6,262,071	07/2001	Crabb, et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes   No	
	BA	WO 98/42705	01.10.98	PCT				
	BB	EP 0 688 772 A1	27.12.95	EPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	G. Cormican, "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluoronated Naphthyridone Compound", <u>Abstracts of the 36th ICAAC</u> , 109 Abst F53 (1996)
CB	J-H. Kwak, "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic", <u>The Journal of Applied Pharmacology</u> (4) pp. 378-384 (1996)
CC	M-K. Seo, "Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 5, pp. 359-367 (1996)
CD	C. Yong Hong, et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)", <u>J. Med. Chem.</u> 40 (22) pp. 3584-3593 (1997)
CE	M-K. Seo et al., "High Performance Liquid Chromatographic Assay of a New Fluoroquinolone, LB20304, in the Plasma of Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 6, pp. 554-558 (1996)
CF	M-J. Ahn, et al., "InVivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice", <u>Yakhak Hoeji</u> Vol. 40, No. 4, pp. 438-441 (1996)
CG	M-J. Ahn, et al., "Effect of a New Fluoroquinolone LB20304a on Microflora of Caecum in Mice", <u>Yakhak Hoeji</u> Vol 40, No. 3, pp. 343-346 (1996)
CH	K-S. Paek, et al., "Factors Affecting In Vitro Activity of LB20304, New Fluoroquinolone", <u>Arch. Pharm. Res.</u> Vol. 19, No. 2, pp. 143-147 (1996)
CI	M-J. Ahn, et al, "Post-Antibiotic Effect of LB20304, A New Quinolone Antibiotic", <u>Yakhak Hoeji</u> Vol. 40, No. 3, pp. 347-350 (1996)
CJ	F. Marco, et al., "Antimicrobial Activity of LB20304, a Fluoronaphthyridone, Tested Against Anaerobic Bacteria", <u>J. Antimicrobial Chemother</u> Vol. 40, No. 4, pp. 605-607 (1997)
CK	M. G. Cormican, et al, "Antimicrobial Activity and Spectrum of LB20304, a Novel Fluoronaphthyridone", <u>Antimicrobial. Agents. Chemotherapy</u> Vol. 41, No. 1, pp. 204-211 (1997)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE STATEMENT**

**BY APPLICANT**

**(Use several sheets if necessary)**

APPLICANT  
Dubois, et al.

FILING DATE  
Herewith

GROUP

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\loretta\applications\p5's\p50928\d1c2\d1c1-1449 form.doc



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. P50928X1D1C2	PREDECESSOR SERIAL NO. 10/325,521
	APPLICANT Dubois, et al.	
	FILING DATE Herewith	GROUP

**CO-PENDING PATENT APPLICATIONS**

Examiner Initial	Attorney Docket No.	US Serial No.	Filing Date	Title	Inventors
	P50954-1	09/569,648	5/12/00	Methods of Use of Quinolone Compounds Against Pneumococcal and Haemophilus Strains	Appelbaum, et al.
	P50955R	09/577,723	5/23/00	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50956R	09/577,731	5/23/00	Methods of Use of Gemifloxacin Compounds Against Fluoroquinolone Resistant Streptococcus Pneumoniae Bacteria	Bast, et al.
	P50959R	09/611,998	7/7/00	Methods of Use of Fluoroquinolone Compounds Against Ciprofloxacin-Resistant And Ciprofloxacin-Sensitive Pathogenic Bacteria	Appelbaum, et al.
EXAMINER				DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTY. DOCKET NO. P50928X1D1C2	PREDECESSOR SERIAL NO. 10/325,521
	APPLICANT Dubois, et al.	
	FILING DATE Herewith	GROUP 1614

**CO-PENDING PATENT APPLICATIONS**

Examiner Initial	Attorney Docket No.	US Serial No.	Filing Date	Title	Inventors
	P50929X1	09/400,144	9/21/99	Methods of Use of Quinolone Compounds Against Anaerobic Pathogenic Bacteria	Citron, et al.
	P50952	09/395,851	9/14/99	Methods of Use of Quinolone Compounds Against Atypical Upper Respiratory Pathogenic Bacteria	Dubois, et al.
	P50953	09/399,855	9/21/99	Methods of Use of Antimicrobial Compounds Against Pathogenic Mycoplasma Bacteria	Crabb, et al.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	